Neumirna Therapeutics, a Copenhagen-based RNA therapeutics company, has appointed Dr. Ferenc Tracik as Chief Medical Officer, according to a search placed by Coulter Partners on May 14, 2026. Tracik takes the position as Neumirna prepares to advance its lead candidate into clinical trials within the next twelve months.
The role positions Tracik to oversee medical and clinical strategy across the company, with direct responsibility for patient safety, regulatory interactions, and external medical affairs. He will partner with Neumirna's Chief Development Officer to guide the lead program NMT.001 into clinical development in early 2027 and contribute to a preclinical program targeting Parkinson's disease. Ellen Donnelly, CEO of Neumirna, said the company had "reached an inflection point: the question is no longer whether the science works, but how quickly we can translate it into an option for patients with urgent unmet need." Donnelly added that Tracik possesses "leadership in CNS development and global regulatory strategy" alongside experience "bringing an ASO therapy for a neurological disease to patients." Nanna Soni, Client Partner at Coulter Partners, emphasized that identifying a physician-leader with Tracik's profile was "critical" given the company's transition toward the clinic.
Tracik brings more than two decades of experience in neurological and rare disease drug development. Most recently, as Chief Medical Officer at NeuroSense Therapeutics, he led global Phase 2 programs in amyotrophic lateral sclerosis and Alzheimer's disease, including a successful Investigational New Drug application submission to the FDA. He departed NeuroSense in April 2026 to pursue the Neumirna role. Earlier in his career, Tracik served as Vice President for Europe, Canada, and Partner Markets at Biogen, where he led the European medical launch of an antisense oligonucleotide therapy for spinal muscular atrophy and established a multinational disease registry. His professional background also includes senior roles at Novartis and Teva. Before entering the pharmaceutical industry, Tracik worked at university clinics of neurology in Berlin and Innsbruck.
Neumirna was founded in 2020 by neuroscience and RNA biology researchers Henrik Klitgaard and Sakari Kauppinen and operates from Copenhagen, Basel, and Boston. The company is developing microRNA-targeted therapies focused on drug-resistant epilepsy and Parkinson's disease. It raised approximately 20 million euros in Series A financing in January 2025, led by Invivo Partners and Angelini Ventures. The company has a proprietary platform for delivering antisense oligonucleotides intrathecally, a targeted approach for central nervous system diseases. Donnelly, a neuroscience veteran with experience at Pfizer and prior roles leading biotech companies, joined Neumirna as CEO in September 2025.
The appointment reflects Neumirna's transition from the discovery and preclinical phase toward clinical development and regulatory engagement. Tracik's experience shepherding antisense oligonucleotide therapies through regulatory approval and commercial launch aligns directly with the company's stated priorities. His appointment signals that Neumirna has completed early-stage scientific validation and is focusing on the clinical and commercial execution necessary to bring RNA-based neurological therapies to market. The hire fits the company's stated direction of accelerating the path from research to patient access for conditions with limited treatment options.
